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Abstract
Background: Gabapentin has shown efficacy in the treatment of chronic neuropathic or mixed pain in adults.
Although pediatric pain specialists have extensive experience with gabapentin for the treatment of neuropathic
pain, its use is off-label. Its efficacy and safety in this context have never been shown. The aim of this trial is to
compare gabapentin with placebo as add-on to morphine for the treatment of severe chronic mixed or neuropathic
pain in children. This trial is part of the European Union Seventh Framework Programme project Gabapentin in
Paediatric Pain (GAPP) to develop a pediatric use marketing authorization for a new gabapentin suspension.
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Methods/design: The GAPP-2 study is a randomized, double-blind, placebo-controlled, multicenter superiority
phase II study in children with severe chronic neuropathic or mixed pain. Its primary objective is to evaluate the
efficacy of a gabapentin liquid formulation as adjunctive therapy to morphine. Sixty-six eligible children 3 months
to 18 years of age with severe pain (pain scores ≥ 7), stratified in three age groups, will be randomized to receive
gabapentin (to an accumulating dose of 45 to 63 mg/kg/day, dependent on age) or placebo, both in addition to
morphine, for 12 weeks. Randomization will be preceded by a short washout period, and treatment will be initiated
by a titration period of 3 weeks. After the treatment period, medication will be tapered during 4 weeks. The primary
endpoint is the average pain scores in the two treatment groups (average of two measures each day for 3 days before
the end-of-study visit [V10] assessed by age-appropriate pain scales (Face, Legs, Activity, Cry, Consolability scale; Faces
Pain Scale–Revised; Numeric Rating Scale). Secondary outcomes include percentage responders to treatment (subjects
with 30% reduction in pain scale), number of episodes of breakthrough pain, number of rescue interventions, number
of pain-free days, participant dropouts, quality of life (Pediatric Quality of Life Inventory), and acceptability of treatment.
Outcomes will be measured at the end-of-study visit after 12 weeks of treatment at the optimal gabapentin dose.
Groups will be compared on an intention-to-treat basis.
Discussion: We hope to provide evidence that the combination of morphine and gabapentin will provide better
analgesia than morphine alone and will be safe. We also aim to obtain confirmation of the recommended pediatric
dose.
Trial registration: EudractCT, 2014-004897-40. Registered on 7 September 2017.
ClinicalTrials.gov, NCT03275012. Registered on 7 September 2017.
Keywords: Gabapentin, Neuropathic pain, Children, Pharmacokinetics
Background
Chronic pain, continuous or recurrent, lasting for more
than 3 months affects 11–35% of children with varying
disabilities [1, 2]. Although nonsteroidal anti-inflammatory
drugs and opioids may be the standard therapy for mild
and severe non-neuropathic pain (non-NP) in both adults
and children, and although tramadol and morphine have
shown efficacy in different types of NP in adults [3–5],
they are not considered to be the first-line medications for
NP syndromes [6–8], owing to concerns regarding long-
term safety. Nevertheless, opioids are used for patients
with severe NP not responding to first-line medications in
acute NP or episodic exacerbation of severe NP. Be-
cause of a lack of appropriate studies in children con-
cerning management of chronic NP, the latter are often
undertreated or pain medication is used off-label.
The antiepileptic drug gabapentin has shown efficacy
in a wide range of neuropathic or mixed pain syndromes.
The mechanism of gabapentin is at the voltage-activated
calcium channels in the central nervous system (CNS),
but the mode of action in the treatment of NP is still
not fully understood. In early studies, gabapentin has
been shown to have a central antiallodynic effect [9] as
well as to inhibit ectopic discharge activity from injured
peripheral nerves [10]. Although originally the hypoth-
esis was that it exerted its antiallodynic effect through
γ-aminobutyric acid-mediated pathways at the spinal
cord and brain level or by antagonism of N-methyl--
D-aspartate receptors, evidence is emerging for antag-
onism of calcium channels in the CNS and peripheral
nerves [9, 11]. Fink et al. showed that gabapentin in the
neocortex of the rat but also in humans inhibits neur-
onal calcium influx, leading to decreased α-amino-3-
hydroxy-5-methyl-4-isoxazole propionic acid receptor
activation and noradrenaline release in the brain [12].
More recently, it was suggested that gabapentin also in-
hibits activation of a nuclear transcription factor and
consequently expression of cyclooxygenase 2 and other
genes involved in inflammation [13].
In adults, randomized controlled trials of gabapentin
have shown its efficacy and safety for the treatment of
postherpetic neuralgia [14, 15], diabetic neuropathy [16],
phantom limb pain [17], spinal cord injury [18], periph-
eral nerve injury [19], and neuropathic cancer pain [20].
Case series and case reports further suggest its efficacy for
analgesia in multiple sclerosis [21, 22], complex regional
pain syndrome type 1, erythromelalgia, trigeminal neural-
gia, peripheral neuropathy, post-thoracotomy neuropathy,
central pain syndromes, and Guillain-Barré syndrome [23].
Efficacy in pediatric pain is based mainly on anecdotal
reports and several open-label, noncontrolled clinical
studies. Gabapentin appears efficacious for the treat-
ment of post-thoracotomy pain, complex regional pain
syndrome type 1, phantom limb pain, and spinal fusion
surgery [24–26].
Hence, although pediatric pain specialists have exten-
sive experience with the use of gabapentin and reports
support its benefits, efficacy and safety have not been
unequivocally demonstrated in well-designed clinical
efficacy and safety studies in the pediatric population.
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In this context, the GAPP (Gabapentin in Paediatric Pain)
project is a European-funded project that comprises a full
pediatric development program for gabapentin in the treat-
ment of chronic neuropathic or mixed pain in children.
The development strategy, requirements, and regulatory
deliverables have been outlined in a pediatric investigation
plan (PIP), which has agreed with and approved by the
European Medicines Agency’s Paediatric Committee.
The PIP includes (1) the development of a liquid oral
gabapentin formulation, (2) the evaluation of gabapentin
safety in juvenile animal toxicity studies (PRE-GABA),
(3) two clinical trials to evaluate the efficacy and safety
of gabapentin as monotherapy (GABA-1) and as adju-
vant therapy (GABA-2), and (4) a modeling bridging
study (GABA-3) to specifically address the paucity of
pharmacokinetic (PK) data in children and enhance the
dose rationale for the pediatric population [27]. The
study protocol presented in this paper concerns the
GABA-2 trial. The primary aim of this specific study
(GABA-2) is to determine the efficacy and safety of gaba-
pentin versus placebo as add-on to morphine in children
with severe chronic neuropathic or mixed pain.
Methods/design
In this randomized, double-blind, placebo controlled,
multicenter superiority phase II study, the efficacy of
gabapentin as add-on to morphine will be compared
with the efficacy and safety of placebo as add-on to
morphine.
Study population
A total of 66 children from 3months to 18 years of age
with chronic (> 3 months) neuropathic or mixed (neuro-
pathic and nociceptive component) pain are being re-
cruited into the trial. Subjects are recruited in several
centers for pediatric pain divided over six European
Union countries (Table 1).
Inclusion criteria
Subjects must fulfill the following inclusion criteria to be
eligible:
1. Children aged 3 months to 18 years
2. Diagnosis of neuropathic or mixed pain
Because there are no validated tools for the diagnosis
of NP in children, diagnosis will be based on Treede et al.
criteria [28]:
 Pain with a distinct neuroanatomically plausible
distribution
 Medical history suggestive of a relevant lesion or
disease affecting peripheral or central somatosensory
system
 Clinical examination with demonstration of a distinct
neuroanatomical distribution by at least one
confirmatory test
 Diagnostic test confirming lesion or underlying disease
(e.g., magnetic resonance imaging or computed
tomographic scan or laboratory test confirming
metabolic disease)
Patients must at least meet one of four mentioned cri-
teria if younger than 3 years old and at least two of four
criteria if older than 3 years of age [28].
For complex regional pain syndrome, the so-called
Budapest criteria will be used for the diagnosis [29].
This means there is continuing pain disproportionate to
the inciting event.
Patient must report at least one symptom in three of
four of the following categories:
 Sensory: allodynia and/or hyperalgesia
 Vasomotor: temperature asymmetry, skin color
changes/asymmetry
 Pseudomotor/edema: edema and/or sweating
 Motor/trophic: motor dysfunction and/or trophic
changes (nail/skin)
This together with at least one sign during evaluation
in two or more of the previous categories and no other
diagnosis can explain the symptoms.
3. Severe pain
Severe pain is defined as intensity 7 or more assessed
during a 3-day screening period using the following
scores according to age: Face, Legs, Activity, Cry, Con-
solability scale (FLACC) for children ages 3 months up
to and including 2 years; Faces Pain Scale–Revised
(FPS-R) for children aged 3 years up to and including
7 years; and the pain Numeric Rating Scale (NRS-11)
for children between 8 and 18 years old. Pain intensity
is assessed two times daily and at least five of six as-
sessments should be available.
4. There should be chronic or recurrent pain for a
period of at least 3 months.
5. Informed consent from parents or legal guardian
6. A stable underlying disease condition and treatment
7. Patients with chemotherapy-induced peripheral
neuropathy when in clinical remission or maintenance
phase of their therapeutic protocol
Exclusion criteria
1. Pain duration of more than 5 years
2. Current use of gabapentin
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3. Current use of strong opioids (morphine, methadone,
fentanyl, oxycodone) or ketamine
4. History of failure to respond to treatment with
gabapentin or opioids for NP
5. History of epilepsy (except febrile seizure)
6. Subjects diagnosed with sickle cell disease
7. Subjects diagnosed with cognitive impairment
8. Subjects who present with current controlled or
uncontrolled comorbid psychiatric diagnosis that
can impair pain diagnosis and assessment
9. Subjects with a history of or current suicidal ideation
or behavior
10. Subjects with a history of substance abuse in
particular opioids
11. Subjects being treated with prohibited concomitant
medication (see Table 2)
12. Subjects with a body mass index below the 5th
percentile or above the 95th percentile for their
age and gender
13. Subjects with renal impairment (i.e., glomerular
filtration rate < 90 ml/min/1.73 m2)
14. Subjects with hepatic impairment (aspartate
transaminase/aAlanine transaminase three times
the upper limit of normal for age)
15. Corticosteroid oral treatment or infiltration needed
for pain caused by infiltration or compression of
neural structures
16. Subjects with clinically relevant abnormal
electrocardiogram (ECG) at the screening visit
Table 1 List of recruiting centers participating in the GABA-2
clinical trial
Albania Qendra Spitalore Universitare Nene Tereza
General Pediatric Clinic - Pediatric Department Rruga e
Dibrës 372, 1000 Tiranë, Albania
Principal Investigator: Prof. Ermira Kola
France Assistance Publique Hôpitaux de Paris - APHP
Hôpital Robert Debré
Centre of Clinical Investigations, INSERM CIC1426
Boulevard Sérurier 48, 75,019, Paris, France
Principal Investigator (Country Coordinator):
Dr. Florentia Kaguelidou
Centre d’évaluation et de traitement de la douleur
Co-investigator: Dr. Sophie Dugué
Assistance Publique Hôpitaux de Paris - APHP
Hôpital Necker
Centre d’évaluation et de traitement de la douleur
Rue de Sèvres 149, 75,015, Paris, France
Principal Investigator: Dr. Brigitte Charron
Hôpital d’enfants Armand Trousseau*
Centre de Référence de la migraine de l’enfant et de
l’adolescent et du Centre de la douleur
26 avenue du Docteur Arnold-Netter, 75,012 Paris
Sub-Investigator: Prof. Barbara Tournaire
Assistance Publique Hôpitaux de Marseille - APHM
Hôpital La Timone
Service de Pédiatrie
Rue Saint-Pierre 264, 13,005, Marseille, France
Principal Investigator: Dr. Cécile Mareau
Centre Hospitalier Régional Universitaire de Lille -
CHRU Lille
Hôpital Roger Salengro
Service de Neuropédiatrie - Consultation Douleur Enfant
Rue Emile Laine, 59,037, Lille, France
Principal Investigator: Dr. Justine Avez-Couturier
Germany Universitaetsklinikum Erlangen
Department of Paediatrics and Adolescent Medicine
Loschgestraße 15, D-91054 Erlangen, Germany
Principal Investigator: Prof. Regina Trollmann
Greece Geniko Nosokomeio Paidon I Agia Sofia
Anaesthetic department & Pain Clinic
Thivon & Papadiamantopoulou 1, 11,527 Athens, Greece
Principal Investigator: Dr. Panagoula Mammi
Italy Azienda Ospedaliero - Universitaria Consorziale
Policlinico di Bari
U.O.C. di Neuropsichiatria Infantile
Piazza Giulio Cesare 11, 70,124, Bari, Italy
Principal Investigator (Country Coordinator):
Prof. Lucia Margari
Azienda Ospedaliera di Padova
Department of Women and Child Health
Via Giustiniani 2, 35,128, Padova, Italy
Principal Investigator: Prof. Franca Benini
Istituto Giannina Gaslini – Genova
Unità Operativa Semplice Dipartimentale di Assistenza
domiciliare e Continuità delle Cure Dipartimento
Testa - Collo e Neuroscienze
Via Gerolamo Gaslini 5, 16,148, Genova, Italy
Principal Investigator: Dr. Luca Manfredini
The
Netherlands
Erasmus Universitair Medisch Centrum Rotterdam -
Sophia Kinderziekenhuis
Intensive Care and Department of Paediatric Surgery
Department of Anesthesiology
Wijtemaweg 80, 3015 CN, Rotterdam, the Netherlands
Table 1 List of recruiting centers participating in the GABA-2
clinical trial (Continued)
Principal Investigator (Country Coordinator):
Prof. Saskia N. De Wildt
University Medical Center Utrecht, Wilhelmina
Kinderziekenhuis
Department of Anesthesiology
Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
Principal Investigator: Dr. Maarten O. Mensink
Table 2 Prohibited concomitant medication
- Tricyclic antidepressants, selective serotonin reuptake inhibitors,
selective noradrenalin reuptake inhibitors, antipsychotics, neuroleptics,
anxiolytics, benzodiazepines, psychostimulants, mono amine oxidase
inhibitors, sedatives
- Anticonvulsant medications as pregabalin, valproic acid, etc.
- All NSAIDs with exception of ibuprofen
- Opioids
- Benzodiazepines
- Ketamine
- Lidocaine
- Medical cannabis
NSAIDs Nonsteroidal anti-inflammatory drugs
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17. Subjects with a known allergy/hypersensibility/
significant intolerance to any component of the
study drugs
18. Subjects with fructose intolerance, diabetes, glucose-
galactose malabsorption, or lactase-isomaltase
deficiency
19. Subjects participating in another clinical trial
20. Subjects scheduled for surgery or in recovery from
surgery within 3 months of baseline assessment
21. Female subjects who are pregnant or lactating
22. Subjects who fail screening or were previously
enrolled in this study
23. Patients with chemotherapy-induced peripheral
neuropathy when in induction phase of their
therapeutic protocol
Screening, assessment, and randomization
Screening period
After obtaining informed consent from the subjects’ par-
ents or legal representatives, during a screening period
to confirm study eligibility, a medical history, including
all relevant lifetime medication and nonpharmacologi-
cal interventions, will be obtained, and concomitant
medication will be recorded. Also, required clinical la-
boratory tests will be done. Venous blood samples will
be taken for standard clinical hematology and biochem-
istry (2.5 ml) together with a serum β-human chorionic
gonadotropin test (in females of childbearing age) (2
ml) and a sample for pharmacogenomics (0.5 ml) and
metabolomics (1 ml).
A washout period of 3 days may be required to discon-
tinue medication potentially interfering with the primary
outcome of pain intensity, with the exception of the res-
cue medications paracetamol and ibuprofen.
Baseline assessment
After the washout period, the patient and, dependent
on the age of the child, the child’s parents will be re-
quested to assess pain intensity twice daily for 3 days to
obtain the average baseline pain intensity. During this
period, rescue medication will be allowed (i.e., paraceta-
mol 15 mg/kg [oral or rectal] four to six times daily to
a maximum daily dose of 4 g or ibuprofen 5–10 mg/kg
[oral] every 6–8 h to a maximum daily dose of 30 mg/
kg/day).
Randomization
After the screening period, the patients return to the trial
center and will be randomized (on V2) at a 1:1 ratio to
one of the treatment groups: gabapentin plus morphine or
placebo plus morphine.
Randomization is performed using ICE version 1.0
software and generated by a statistician not involved in
data analysis of trial results. After randomization login,
a blinded message is sent to the investigator, and an
unblinded message is sent to the pharmacy.
Patients are stratified into three age groups (3 months
to 3 years, 3 years to 8 years, and 8 years to 18 years) with
pain scores validated for that age group.
Treatment period
Dose and dose optimization
During the first 3 weeks of treatment period 4 (V3–V6
in the participant timeline) (Fig. 1), visits will be sched-
uled to assess safety and tolerability and to titrate liquid
gabapentin (75 mg/ml) to an optimal, weight-based (two
weight groups, 5 to ≤ 15 kg and > 15 kg) tolerable dosage.
A dose will be indicated as optimal if the subject has
reached a pain intensity < 4/10 in all pain assessments in
the last 48 h (n = 4) or the maximum tolerable dose. Only
one dose reduction is allowed during the optimization
period (Table 3).
All children will have a titration in morphine starting
at 0.6 mg/kg/day to a maximum dose of 1.2 mg/kg/day
four times daily from days 1 to 5, based on the World
Health Organization (WHO) guidelines of 2012 [30].
For patients with a body weight of 30 kg or less, a liquid
formulation will be used during titration and mainten-
ance phases. For patients with a body weight of 30 kg
or more, a solid immediate release formulation will be
used during titration phase, which will be converted to
a similar daily dose solid extended release formulation
during maintenance phase. During all visits in the dose
optimization and maintenance period, adverse effects of
Fig. 1 Participant timeline
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morphine will be closely monitored (e.g., constipation,
for which laxatives can be given).
At dose optimization visit V5 or V6 (or at end-of-
study [EOS] visit V10), four venous blood samples will
be taken for assessment of PK: One predosing and three
at different times postdosing (four times 1.5 ml and for
children less than 15 kg four times 1ml).
Fixed-dose maintenance period
After dose optimization, patients will continue to take
medication (gabapentin or placebo) next to morphine
for an additional 12 weeks. Dose adjustments are not
allowed during the maintenance period.
End of study
For all patients who terminate or complete the dose
maintenance period, medication will be tapered accord-
ing to a schedule over 0–4 weeks. During this tapering
period, site staff will contact the patients to ensure that
they are complying with the taper schedule. At EOS visit
V10, venous blood sampling will be done once again
(standard clinical hematology and biochemistry [2.5 ml]
and metabolomics [1 ml]).
Study taper and follow-up period
End of taper
All patients who are tapered off medication will return
for a visit 1–4 weeks after their EOS visit for the collec-
tion of final safety evaluations.
Follow-up
Seven days after the last dose of investigational medica-
tion, follow-up by phone will take place to collect infor-
mation about pain intensity, global health, and ongoing
or new (serious) adverse events and concomitant medi-
cation until all safety concerns are resolved.
Blinding
Gabapentin and placebo (oral liquid formulation) will be
indistinguishable in appearance to maintain the study
blinding. Also, labeling will not allow recognition of ac-
tual treatment. During the trial, blinding will be broken
by the investigator for emergency purposes only, where
knowledge of the blinded treatment could influence
further patient care. In addition, the safety contact will
unblind safety reports, as per regulatory requirements.
Study blinding will be broken after database lock.
Efficacy measurement
The following scales will be used to assess pain intensity
at all visits throughout the study. The FLACC scale is
used for children between 3 months and 7 years of age
who are unable to self-report their pain. It is a five-
item scale that raters (investigators, parents) use to
score in five categories (Face, Legs, Activity, Cry, and
Consolability), each assigned a score of 0, 1, or 2 and
total score between 0 and 10.
The FPS-R is a self-report measure of pain intensity. It
consists of six line drawings of faces that are scored 0
to 10. In this study, the FPS-R will be used for assess-
ment of pain in children 3 years and older because it
has not been validated for younger children. In children
of 3 and 4 years old who are unable to self-report using
the FPS-R, the FLACC scale will be used.
The Numeric Rating Scale (NRS-11) is designed for
pain score to be used by children from 8 years of age.
The user has the option to verbally rate their scale from
0 to 10 or to place a mark on a line indicating their level
of pain, with 0 meaning absence of pain and 10 meaning
the most intense pain possible.
To be able to compare data from the different pain
scores, all scores will be reported on a scale of 0–10, as
indicated by the individual scores.
Pain will be assessed at the following time points:
1. Baseline assessment: average pain score of twice-daily
assessment on 3 consecutive days
2. During trial: daily in the morning and when
breakthrough pain is noticed
3. Endpoint: average pain score of twice-daily
assessments on 3 consecutive days
Furthermore, parents and/or subjects are asked to keep
a daily patient diary recording the following items: study
drug intake changes, comedication intake including rescue
medication, adverse events, and abnormalities in sleep.
Additionally, the following items will be scored:
 Global satisfaction with treatment (at EOS visit V10)
using NRS-11
Table 3 Dose optimization schedule of gabapentin
Weight group V2 V3 V4 V5 V6
5–15 kg 7mg/kg/day
corresponding
to 0,09 ml/kg/day
14 mg/kg/day
corresponding
to 0,19 ml/kg/day
21 mg/kg/day
corresponding
to 0,28 ml/kg/day
42mg/kg/day
corresponding
to 0,56 ml/kg/day
63 mg/kg/day
corresponding
to 0,84 ml/kg/day
> 15 kg 5mg/kg/day
corresponding
to 0,07 ml/kg/day
10 mg/kg/day
corresponding
to 0,13 ml/kg/day
15 mg/kg/day
corresponding
to 0,2 ml/kg/day
30mg/kg/day
corresponding
to 0,4 ml/kg/day
45 mg/kg/day
corresponding
to 0,6 ml/kg/day
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 Clinical Global Impressions Scale (CGI-EI
[Investigator]) at V2, V6, and EOS V10
 Patient Global Impression of Change (PGIC) Scale
at V6 and EOS V10
 Pediatric Quality of Life Inventory (PedsQL) Generic
Core Scale
 Five Point Facial Hedonic Scale at EOS V10 for
acceptability of the oral suspension
 Adverse events collection
 Columbia Suicide Severity Rating Scale (C-SSRS) at
V1 and EOS V10
 Modified Overt Aggression Scale at V2, V6, and
EOS V10
Outcome measurements
The primary outcome of the study is the average pain
score (defined as average pain score of twice-daily as-
sessments of 3 consecutive days) at the end of the study
period in both treatment groups. Secondary endpoints
are percentage of responders with 30% reduction in pain
score, average daily pain intensity by age-appropriate scale,
observational pain assessment with use of NRS-11 by par-
ents/caregivers and investigator at each visit, number of
episodes of breakthrough pain > 4/10 pain score and use
of rescue medication, number of rescue interventions,
number of pain-free days with < 4/10 pain score without
rescue medication, participant dropouts due to lack of effi-
cacy, total cumulative weight dose of each rescue drug,
quality of life scored with the PedsQL at baseline (V2) and
EOS visit (V10), acceptability of treatment (Facial Hedonic
Scale) at EOS visit, global satisfaction with treatment
(NRS-11 completed by parent/patient) at EOS visit,
CGI-S at V6 and EOS (CGI-S by investigator), patient/
parent PGIC at V6 and EOS, PK parameters: apparent
clearance (CL/F), apparent volume of distribution (Vd/
F), absorption rate constant (Ka), area under the curve
(AUC), maximum (peak) concentration (Cmax), time
of maximum concentration (Tmax), concentration at
steady-state (Css), minimum concentration (Cmin) in-
cidence of adverse events, percentage of adverse
events, percentage of subjects discontinuing the trial due
to adverse events, aggressive behavior in children > 6
years old (Retrospective-Modified Overt Aggression
Scale) at V2–V6 and EOS, and suicidal ideation
(C-SSRS) at V1 and EOS.
Study procedures
The protocol structure follows the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) 2013
statement. The SPIRIT schedule with a complete overview
of the study procedures for this trial is summarized in Fig. 2.
The complete SPIRIT checklist for the study is provided in
Additional file 1.
Statistical analysis
Sample size calculation
A total sample size of 66 is needed. It will allow detection
of a significant difference between morphine plus placebo
and morphine plus gabapentin groups in mean pain scores
at EOS. Mean baseline pain scores of 8.5 are assumed for
both groups, with estimated EOS pain scores of 5.4 for
morphine alone versus 4.5 for morphine plus gabapentin
based on percentage change in pain scores in a previous
trial in adults [31].
A minimum number of patients is defined per age
group: (1) at least 5 patients aged 3 months to less than
3 years, (2) at least 15 patients aged 3 years to less than
7 years, and (3) at least 20 patients aged 7 years to less
than 18 years. No maximum number of patients per age
group is specified. A two-tailed test will be applied with
a significance level of 0.5 and a power of 80%, and 10%
dropout is anticipated.
Type of analysis
The primary efficacy analysis of this study is aimed at
assessing the superiority of treatment with morphine
and gabapentin compared with morphine and placebo.
The hypothesis to be tested is that the average pain scores
(average of two measures each day for 3 days before EOS
visit V10) assessed by age-appropriate pain scales (FLACC,
FPS-R, NRS-11) are lower in the treatment group (mor-
phine + gabapentin) than in the control group (morphine
+ placebo).
The primary analysis of efficacy will be conducted using
one-way analysis of covariance (ANCOVA) with baseline
average pain score as a covariate. Other covariates will
include center, treatment, and age (three subgroups). A
second ANCOVA model including a treatment × cen-
ter interaction term will be used to assess consistency
across sites.
Intergroup differences as breakthrough pain and fre-
quency and dosage of rescue medication will be assessed
using sample t test or Wilcoxon-Mann-Whitney tests.
Statistical analysis will be performed using IBM SPSS
Statistics 21 (IBM, Armonk, NY, USA) or SAS 9.4 (SAS
Institute, Inc., Cary, NC, USA) software for PC.
Pharmacokinetic-pharmacodynamic analysis
PK data will be analyzed by nonlinear mixed effects mod-
eling with NONMEM (version 7.2; ICON Development
Solutions, Dublin, Ireland) to estimate PK parameters, in-
cluding volume distribution, clearance of gabapentin and
morphine, and variability and precision. Also, influence of
potential covariates will be evaluated.
Using predicted drug concentrations, a population
PK-pharmacodynamic (PD) model will be developed to
link drug exposure to pain response.
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Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure with overview of the study procedures
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Ethical approval
Ethical approval was obtained from the Medical Ethical
Committee of the Erasmus Medical Centre, Rotterdam,
The Netherlands.
Medical ethical review is under way in the other par-
ticipating centers (EudractCT, 2014-004897-40), and the
study is registered at ClinicalTrials.gov (NCT03275012).
DSMC
The study safety and progress will be reviewed by an in-
dependent data and safety monitoring committee (DSMC)
according to the DSMC charter. All adverse effects re-
ported by the subjects or observed by investigators or
staff will be recorded. A continuous evaluation will be
performed by an independent DSMC. In case of dis-
proportionate adverse effects or prolonged inclusion,
the DSMC can decide to terminate the study. No interim
analysis for efficacy is planned.
Discussion
The GABA-2 study is an exploratory, randomized, double-
blind, placebo-controlled, multicenter study designed to
evaluate the efficacy of gabapentin added to morphine in
pediatric patients with severe neuropathic or mixed pain.
Although strong opioid use for benign pain is met with
cultural barriers in many countries, the use of morphine is
recommended by the WHO guidelines for persistent pain
in children as a first-line treatment [30]. Also, the use of
morphine for NP is questioned by practitioners, but tram-
adol and morphine have shown efficacy in several ran-
domized controlled trials concerning different types of NP
[3–5, 32] and are therefore advised in the guidelines from
the International Association for the Study of Pain for the
treatment of NP in adults [32, 33].
Hence, the use of morphine for severe NP in children
should be seriously considered and studied clinical trials.
Because treatment with first-line agents such as antide-
pressants and anticonvulsants as monotherapy for severe
NP is not always sufficient [34], and because data show
a synergistic effect of gabapentin when added to mor-
phine in adult patients with NP, this design was chosen
for the children with the most severe pain (pain scores 7
or higher on a scale of 0–10).
Although opioids other than morphine, based on PD
properties, might be more suitable [8], they were consid-
ered inappropriate for this study because of unavailabil-
ity in some of the participating countries.
Chronic pain, specifically NP in children, is often diffi-
cult to treat. Children are often undertreated owing to a
lack of evidence or medication is used off-label because
it often is not registered for use under a certain age. For
example, in The Netherlands, gabapentin is not regis-
tered for treatment of NP in patients younger than 12
years. Moreover, high-quality studies investigating the
efficacy and safety of gabapentin for this indication in
children are lacking. Hence, we believe our trial is neces-
sary and timely.
Pediatric PK studies of gabapentin [35, 36] have shown
that oral clearance of gabapentin was directly proportional
to creatinine clearance, which is higher for children youn-
ger than 5 years of age than in older children and highly
variable in infants younger than 1 year of age. Therefore, a
PK analysis was performed by simulating different dosing
scenarios to evaluate dosing requirements to ensure ef-
fective drug concentrations of gabapentin as described in
treatment of adult NP [37]. Based on this analysis, an ap-
propriate dosing schedule based on weight bands for prac-
tical considerations will be used.
Justification of this dosing regime will be further inves-
tigated by assessing drug exposure using sparse sampling
techniques. A correlation between exposure and analgesia
will be explored.
The dosing regimen for morphine and slow-release
morphine is based on the WHO guideline for morphine
in children [30], and it will be titrated on the basis of
tolerability in the first days of the active treatment phase
of the trial. Slow-release morphine with lower daily dosage
would be the preferred formulation, but it is not available
or registered for all age groups. Therefore, depending on
the body weight of the patient as well as on availability
and registration in the participating countries, immediate-
release formula or tablet morphine is chosen for the titra-
tion phase. Slow-release morphine is chosen for patients
above 30 kg during the maintenance period of the study.
The primary endpoint of the study will be the differ-
ences in average pain scores for the two treatment
groups (average of two measures each day for 3 days
before the EOS visit) assessed by the age-appropriate
pain scales (FLACC, FPS-R, NRS-11). Because the age
range of the study population is wide, different pain
scores were needed to ensure the most optimal scale
for the different age groups. FLACC is a validated,
observer-based scores for younger children. For
school-age children, the FPS-R was chosen as a vali-
dated self-reported pain score, whereas the NRS-11
was considered most appropriate for older children.
We realize that these scores are only validated for
acute pain, but in the absence of validated pain tools
for chronic pain, these scores were considered the best
validated alternatives. Another limitation is that the data
need to be analyzed in an aggregate way (i.e., all age
groups together). For this reason, we also used scores that
are expressed on a 10-point scale and can be analyzed to-
gether, although we acknowledge that cross-validation of
the absolute scores has not been done, to our knowledge.
In general, a pain score of 4 is accepted as a cutoff for pain
that needs treatment for all scores; hence, we considered
the combined use of scores acceptable.
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To our knowledge, this is the first randomized con-
trolled trial studying the effectiveness of the combination
therapy morphine and gabapentin for pain in children.
Although very challenging in design and in potential re-
cruitment and retention of patients, we believe this trial
will provide more solid evidence of the efficacy of gaba-
pentin in combination with morphine to ultimately im-
prove the treatment of severe NP in children.
Trial status
For the Gaba-2 study, ethical approval has been obtained
in one of the participating centers, and the study is under
review in the other centers. No patients have yet been
included.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 122 kb)
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